Linda White, NP
Family · Smithfield, NCNPI 1174975387
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 581 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Viiv Healthcare Company at 39.5% of the total. Among family clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 581 payments — averaging $21.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$5K
- Gilead$2K
- AbbVie$1K
- Melinta Therapeutics, LLC$1K
- Paratek Pharmaceuticals, Inc.$898
- Merck$648
- plus $2K from 19 others
What the payments were for
- Food & beverage$12,22398%
- Education$2962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 216 | $4,942 |
| Gilead | 111 | $1,895 |
| AbbVie | 56 | $1,080 |
| Melinta Therapeutics, LLC | 31 | $1,055 |
| Paratek Pharmaceuticals, Inc. | 38 | $898 |
| Merck | 41 | $648 |
| Shionogi Inc | 17 | $380 |
| Insmed, Inc. | 10 | $254 |
| Johnson & Johnson | 15 | $252 |
| Janssen Products, LP | 3 | $214 |
| Cumberland Pharmaceuticals, Inc. | 8 | $160 |
| Theratechnologies Inc. | 5 | $160 |
| Lilly USA, LLC | 6 | $149 |
| Electromed, Inc. | 5 | $68 |
| Mylan Specialty L.p. | 3 | $65 |
| Novo Nordisk | 3 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| Mayne Pharma Commercial LLC | 2 | $33 |
| AstraZeneca | 2 | $33 |
| La Jolla Pharmaceutical Company | 2 | $29 |
| Astellas Pharma US Inc | 1 | $28 |
| Organogenesis Inc. | 1 | $27 |
| Smith+Nephew | 1 | $27 |
| Boston Scientific | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,519 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 471 | $1,939,087 |
| DovatoDolutegravir Sodium/Lamivudine | 146 | $455,517 |
| RukobiaFostemsavir Tromethamine | 27 | $259,392 |
| CabenuvaCabotegravir/Rilpivirine | 32 | $151,634 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 27 | $143,284 |
| TivicayDolutegravir Sodium | 51 | $128,017 |
| DescovyEmtricitabine/Tenofov Alafenam | 27 | $65,792 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 11 | $46,391 |
| Isentress HdRaltegravir Potassium | 12 | $23,482 |
| EdurantRilpivirine Hcl | 13 | $18,241 |
| Fosfomycin Tromethamine | 27 | $8,661 |
| Fluconazole | 42 | $1,370 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 13 | $1,073 |
| Rifampin | 11 | $1,014 |
| ValacyclovirValacyclovir Hcl | 26 | $990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,895 | $2,004,879498 claims |
| Viiv Healthcare CompanyDovato, Rukobia, Cabenuva, Tivicay | $4,942 | $994,560256 claims |
| Janssen Products, LPSymtuza | $214 | $143,28427 claims |
| MerckIsentress Hd | $648 | $23,48212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Smithfield
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.